Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Tailoring therapy for patients with multiple myeloma to improve outcomes

Elizabeth O'Donnell • 28 Sep 2023
IMS 2023
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Lenalidomide
MAIA

Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the importance of tailoring treatment approaches for patients with multiple myeloma. Decisions should be made by taking into account factors such as the patient’s age, frailty and comorbidities, as well as the side effects of agents being used. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elizabeth O'Donnell

SMM & MGUS: clinical relevance, the PROMISE study & the role of genomics
Elizabeth O'Donnell et al. • 25 Mar 2024
2:04
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma: the SKylaRk trial
Elizabeth O'Donnell • 11 Dec 2023
0:50
Tools to improve frailty assessment in patients with multiple myeloma
Elizabeth O'Donnell • 28 Sep 2023
0:38
SKylaRk trial update: Isa-KRd in newly diagnosed, transplant-eligible multiple myeloma
Elizabeth O'Donnell • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals